FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening

from JCO Precision Oncology Conversations

JCO PO author Dr. Wainberg at UCLA shares insights into the JCO PO article, "Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial." Host Dr. Rafeh Naqash and Dr. Wainberg discuss how FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expression. TRANSCRIPT TO COME

Episode metadata supplied by the publisher feed · Published Jan 21, 2026

Embed this episode

Attribution link and audio player

Ready to play

FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening

0:00 19:38

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JCO Precision Oncology Conversations?

This episode is 19 minutes long.

When was this JCO Precision Oncology Conversations episode published?

This episode was published on January 21, 2026.

Can I download this JCO Precision Oncology Conversations episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!